Results 161 to 170 of about 68,966 (291)
Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
Journal of the European Academy of Dermatology and Venereology, EarlyView.In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio +16 more
wiley +1 more source
Journal of Sleep Research, EarlyView.ABSTRACT Mounting evidence shows sex‐based differences in sleep experiences and outcomes, including the prevalence of insomnia disorder. However, the impact of biological sex on brain oscillations during sleep remains poorly understood, especially in the context of insomnia disorder. This is a notable gap, given that neurophysiological aspects of sleep
Nyissa A. Walsh +5 more
wiley +1 more source
The Role of Antioxidants in the Management of Polycystic Ovary Syndrome. [PDF]
Antioxidants (Basel)Sorić T +5 more
europepmc +1 more source
Pancreatic and adrenal development and function in an ovine model of polycystic ovary syndrome [PDF]
Polycystic Ovary Syndrome (PCOS) is a complex disorder encompassing reproductive and metabolic dysfunction. Ovarian hyperandrogenism is an endocrine hallmark of human PCOS.
Ramaswamy, Seshadri
core
Associations Between Body Composition and Metabolic Health in Children With Obesity
Maternal &Child Nutrition, EarlyView.ABSTRACT Childhood obesity is an increasing public health problem with heterogeneous metabolic health outcomes. In children, distinguishing differences in body composition between individuals with metabolically healthy obesity (MHO) and those with metabolic syndrome (MS) may be useful for understanding the impact of body composition on metabolic health.
Desiree Lopez‐Gonzalez +5 more
wiley +1 more source
The stromal microenvironment of ovary: a novel area in polycystic ovary syndrome. [PDF]
J Ovarian ResWang H, Zhou H, Liu Z, Zhao T, Zhang C.
europepmc +1 more source
Obesity Reviews, EarlyView.ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh +14 more
wiley +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, EarlyView.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
The impact of daily steps on polycystic ovary syndrome patients. [PDF]
Front Endocrinol (Lausanne)Wang T, Zhang L, Ma L, Luo X, Li C.
europepmc +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, EarlyView.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source